ir.prothena.com
Investor Relations - Prothena Corporation plcThe Investor Relations website contains information about Prothena Corporation plc business for stockholders, potential investors, and financial analysts.
http://ir.prothena.com/
The Investor Relations website contains information about Prothena Corporation plc business for stockholders, potential investors, and financial analysts.
http://ir.prothena.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Tuesday
LOAD TIME
0.1 seconds
PAGES IN
THIS WEBSITE
19
SSL
EXTERNAL LINKS
55
SITE IP
206.200.251.19
LOAD TIME
0.14 sec
SCORE
6.2
Investor Relations - Prothena Corporation plc | ir.prothena.com Reviews
https://ir.prothena.com
The Investor Relations website contains information about Prothena Corporation plc business for stockholders, potential investors, and financial analysts.
ir.prothena.com
Historic Stock Lookup - Prothena Corporation plc
http://ir.prothena.com/stocklookup.cfm
NEOD001 for AL and AA Amyloidosis. PRX002 for Parkinson’s disease. PRX003 for Inflammatory Disease and Metastatic Cancers. Events & Presentations. Financials & Filings. Electronic Delivery ». Adjusted historic prices for the week of November 7, 2016. Nov 7, 2016. Year End Stock Prices. 2016 Prothena Corporation plc | Terms and Conditions. 124; Privacy Policy.
Analyst Coverage - Prothena Corporation plc
http://ir.prothena.com/analysts.cfm
NEOD001 for AL and AA Amyloidosis. PRX002 for Parkinson’s disease. PRX003 for Inflammatory Disease and Metastatic Cancers. Events & Presentations. Financials & Filings. Electronic Delivery ». Prothena Corporation plc is covered by the following analysts. Bank of America Merrill Lynch. Geoff Meacham, Ph.D. Kennen MacKay, Ph.D. Jerry Isaacson, Ph.D. Heather Behanna, Ph.D. 2016 Prothena Corporation plc | Terms and Conditions. 124; Privacy Policy.
Investor Relations - Prothena Corporation plc
http://ir.prothena.com/index.cfm
NEOD001 for AL and AA Amyloidosis. PRX002 for Parkinson’s disease. PRX003 for Inflammatory Disease and Metastatic Cancers. Events & Presentations. Financials & Filings. Electronic Delivery ». Aug 31, 2016. Delayed 20 min., by eSignal. Aug 30, 2016. Prothena to Participate in Upcoming September Investor Conferences. Aug 2, 2016. Prothena Reports Second Quarter 2016 Financial Results; Provides R&D Update. View all press releases ». 2016 Prothena Corporation plc | Terms and Conditions. 124; Privacy Policy.
Press Releases - Prothena Corporation plc
http://ir.prothena.com/releases.cfm
NEOD001 for AL and AA Amyloidosis. PRX002 for Parkinson’s disease. PRX003 for Inflammatory Disease and Metastatic Cancers. Events & Presentations. Financials & Filings. Electronic Delivery ». Aug 30, 2016. Prothena to Participate in Upcoming September Investor Conferences. Aug 2, 2016. Prothena Reports Second Quarter 2016 Financial Results; Provides R&D Update. Jul 6, 2016. Prothena to Participate in Cantor Fitzgerald's 2nd Annual Healthcare Conference. DUBLIN, Ireland, July 06, 2016 (GLOBE NEWSWIRE) - P...
Events & Presentations - Prothena Corporation plc
http://ir.prothena.com/events.cfm
NEOD001 for AL and AA Amyloidosis. PRX002 for Parkinson’s disease. PRX003 for Inflammatory Disease and Metastatic Cancers. Events & Presentations. Financials & Filings. Electronic Delivery ». Sep 7, 2016. Credit Suisse Antibody Day. Credit Suisse Antibody Day. Please sign up for email alert notification. Sep 8, 2016. Citi's 11th Annual Biotech Conference. Citi's 11th Annual Biotech Conference. Please sign up for email alert notification. Sep 12, 2016. Morgan Stanley Global Healthcare Conference. POSTER: ...
TOTAL PAGES IN THIS WEBSITE
19
NEOD001 for AL Amyloidosis - Prothena Corporation
http://www.prothena.com/pipeline/neod001-for-al-and-aa-amyloidosis
NEOD001 for AL Amyloidosis. PRX002 for Parkinson’s disease. PRX003 for Psoriasis and Other Inflammatory Diseases. Events & Presentations. Financials & Filings. NEOD001 for AL Amyloidosis. PRX002 for Parkinson’s disease. PRX003 for Psoriasis and Other Inflammatory Diseases. Our Phase 3 VITAL Study website is now online. NEOD001 for AL Amyloidosis. Our Phase 3 VITAL Study website is now online. Prothena’s NEOD001 is a monoclonal antibody that specifically targets the amyloid that accumulates in AL amyloido...
Publications - Prothena Corporation
http://www.prothena.com/publications
NEOD001 for AL Amyloidosis. PRX002 for Parkinson’s disease. PRX003 for Psoriasis and Other Inflammatory Diseases. Events & Presentations. Financials & Filings. Select Publications from the Prothena Team:. 2A4 Binds Soluble and Insoluble Light Chain Aggregates from AL Amyloidosis Patients and Promotes Clearance of Amyloid Deposits by Phagocytosis. DOI: 10.1080/13506129.2016.1205974 (2016). Novel Conformation-specific Monoclonal Antibodies Against Amyloidogenic Forms of Transthyretin. Melanoma Cell Adhesio...
Management Team - Prothena Corporation
http://www.prothena.com/company/management-team
NEOD001 for AL Amyloidosis. PRX002 for Parkinson’s disease. PRX003 for Psoriasis and Other Inflammatory Diseases. Events & Presentations. Financials & Filings. Our Phase 3 VITAL Study website is now online. Dale B. Schenk, PhD. President and Chief Executive Officer, Director. A W (Bill) Homan. Mr Homan has served as our Chief Legal Officer since 2014. Prior to joining Prothena, he was Senior Vice President, General Counsel and Secretary of Complete Genomics, Inc., a position he held from 2012 unt...Mr Ho...
PRX002 for Parkinson’s disease and other related synucleinopathies - Prothena Corporation
http://www.prothena.com/pipeline/prx002-for-parkinsons-disease
NEOD001 for AL Amyloidosis. PRX002 for Parkinson’s disease. PRX003 for Psoriasis and Other Inflammatory Diseases. Events & Presentations. Financials & Filings. NEOD001 for AL Amyloidosis. PRX002 for Parkinson’s disease. PRX003 for Psoriasis and Other Inflammatory Diseases. Our Phase 3 VITAL Study website is now online. PRX002 for Parkinson’s disease and other related synucleinopathies. Prothena’s scientists have generated monoclonal antibodies targeting α-synuclein. We have designed these antibodies ...
Science - Prothena Corporation
http://www.prothena.com/science
NEOD001 for AL Amyloidosis. PRX002 for Parkinson’s disease. PRX003 for Psoriasis and Other Inflammatory Diseases. Events & Presentations. Financials & Filings. Prothena Corporation plc (Nasdaq: PRTA) is targeting proteins with its novel immunotherapy programs to transform patients’ lives. These same scientists also pioneered significant scientific discoveries with cell adhesion molecules, leading to the discovery, development and commercialization of Tysabri. The global Phase 3 registrational trial, The ...
Overview - Prothena Corporation
http://www.prothena.com/pipeline/overview
NEOD001 for AL Amyloidosis. PRX002 for Parkinson’s disease. PRX003 for Psoriasis and Other Inflammatory Diseases. Events & Presentations. Financials & Filings. NEOD001 for AL Amyloidosis. PRX002 for Parkinson’s disease. PRX003 for Psoriasis and Other Inflammatory Diseases. Our Phase 3 VITAL Study website is now online. Inflammatory diseases, including Psoriasis. 2016 Prothena Corporation plc | Terms and Conditions. 124; Privacy Policy.
Board of Directors - Prothena Corporation
http://www.prothena.com/company/board-of-directors
NEOD001 for AL Amyloidosis. PRX002 for Parkinson’s disease. PRX003 for Psoriasis and Other Inflammatory Diseases. Events & Presentations. Financials & Filings. Our Phase 3 VITAL Study website is now online. Prothena’s Board of Directors is comprised of accomplished, global biotechnology and pharmaceutical leaders with extensive governance experience and expertise in research, development and commercialization of novel products to treat patients with unmet medical needs. Lars G. Ekman, MD, PhD. Mr Collier...
Overview - Prothena Corporation
http://www.prothena.com/company/overview
NEOD001 for AL Amyloidosis. PRX002 for Parkinson’s disease. PRX003 for Psoriasis and Other Inflammatory Diseases. Events & Presentations. Financials & Filings. Our Phase 3 VITAL Study website is now online. Prothena Corporation plc (Nasdaq: PRTA) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies for the potential treatment of diseases that involve amyloid or cell adhesion. PRX002 is in a Phase 1 multiple ascending d...
Partnerships - Prothena Corporation
http://www.prothena.com/partnerships
NEOD001 for AL Amyloidosis. PRX002 for Parkinson’s disease. PRX003 for Psoriasis and Other Inflammatory Diseases. Events & Presentations. Financials & Filings. Prothena Corporation plc (Nasdaq: PRTA) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. 2016 Prothena Corporation plc | Terms and Conditions. 124; Privacy Policy.
PRX003 for Psoriasis and Other Inflammatory Diseases - Prothena Corporation
http://www.prothena.com/pipeline/prx003-for-psoriasis-and-other-inflammatory-diseases
NEOD001 for AL Amyloidosis. PRX002 for Parkinson’s disease. PRX003 for Psoriasis and Other Inflammatory Diseases. Events & Presentations. Financials & Filings. NEOD001 for AL Amyloidosis. PRX002 for Parkinson’s disease. PRX003 for Psoriasis and Other Inflammatory Diseases. Our Phase 3 VITAL Study website is now online. PRX003 for Psoriasis and Other Inflammatory Diseases. Anti-MCAM antibodies also may be useful for treating metastatic cancers, including melanoma. Prothena has generated a portfolio of mon...
TOTAL LINKS TO THIS WEBSITE
55
Prologis
Skip to main content. Stock Quote and Chart. Fixed Income and Corporate Ratings. Stock Quote and Chart. Fixed Income and Corporate Ratings. Annual Net Operating Income. Most Sustainable Companies Globally. Q4 2017 Supplemental Financial Report (PDF). Q1 2018 FINANCIAL RESULT WEBCAST AND CONFERENCE CALL. Prologis to Announce First Quarter 2018 Results April 17. Subscribe to get the latest investor news and information delivered directly to your inbox.
Investor Relations :: Propanc Health Group Corporation (PPCH)
Ended June 30, 2016. Research and development YTD. Net cash used in operations YTD. Jan 11, 2017. Propanc Receives Allowance of Key Patent Application for Method of Treating Solid Tumors in the US. Ended Sep 30, 2016. Sign Up For E-Mail Alerts. View Detailed Stock Info. Propanc Health Group Corporation. View Board of Directors. New York, NY 10022. Corporate Stock Transfer Inc. 3200 Cherry Creek South Drive. Denver, CO 80209. 2016 Propanc Health Group Corporation.
Overview :: Protalex, Inc. (PRTX)
Protalex, Inc. on LinkedIn. Protalex, Inc. on Facebook. Protalex, Inc. on Twitter. Protalex, Inc. on Google Plus. Patents and Intellectual Property. Sign up for email alerts. Be the first to receive breaking news. Protalex Receives Positive Interim Review from Independent Safety Monitoring Committee in Its European Phase 1b Study of PRTX-100 to Treat Immune Thrombocytopenia. May 2, 2016. Nov 30, 2016. Officers & Directors. Arnold P. Kling. Kirk M. Warshaw. Chief Financial Officer, Secretary and Director.
Investors | Investors | Proteon Therapeutics
Proteon Therapeutics is a biopharmaceutical company developing vonapanitase. Formerly PRT-201), an investigational drug to improve arteriovenous fistula. PAD) The company is headquartered in Waltham, MA. 160; 0.82. Data as of 08/17/15 4:00 pm ET. Proteon Therapeutics Announces Second Quarter 2015 Financial Results. Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease. Proteon Therapeutics, Inc.
Investor Relations - Prothena Corporation plc
NEOD001 for AL and AA Amyloidosis. PRX002 for Parkinson’s disease. PRX003 for Inflammatory Disease and Metastatic Cancers. Events & Presentations. Financials & Filings. Electronic Delivery ». Day High: 62.47. Day Low: 58.95. Aug 17, 2015. Delayed 20 min., by eSignal. Aug 4, 2015. Prothena Reports Second Quarter 2015 Financial Results and Provides R&D Update. Jun 29, 2015. Prothena Announces Addition of Seasoned Executive to Board of Directors. View all press releases ». 124; Privacy Policy.
Investor Relations :: Provision Holding, Inc. (PVHO)
Total Year End Revenue for the fiscal year ending. June 30, 2016. Nearly 500 kiosks installed in a leading pharmacy chain. Provision Upgrades 3D Savings Center Software. Dec 28, 2016. V20 adds user-friendly loyalty card interface CHATSWORTH, Calif., Dec. 28, 2016 (GLOBE NEWSWIRE) - Provision Interactive Technologies, Inc. ("Provision"), a subsidiary of Provision Holding, Inc. (OTCQB:PVHO),…. 9th Annual LD Micro Main Event. Dec 7, 2016 9:00am PST. Quarter Ended Sep 30, 2016. Sign Up for E-mail. Provision ...
Institutional Research Interest Group – Strengthening IR Community and Capacity at Penn State
Institutional Research Interest Group. Strengthening IR Community and Capacity at Penn State. Welcome to the website of the Penn State Institutional Research Interest Group. We are guided by the belief that although there are many excellent data and analysis resources at Penn State, we can do a better job of coordination, communication, and sharing in the increasingly pertinent domain of institutional research. To keep up to date with upcoming events related to IR. Why an IR Interest Group? Planning Rese...
Inżynieria Rolnicza
ISSN 2083-1587 / eISSN 2449-5999. Author List by Place of Work. Search for a Word. 2015 Volume 19 Issue 4 (156). 2015 Volume 19 Issue 3 (155). 2015 Volume 19 Issue 2 (154). 2015 Volume 19 Issue 1 (153). 2014 Volume 18 Issue 4 (152). 2014 Volume 18 Issue 3 (151). 2014 Volume 18 Issue 2 (150). 2014 Volume 18 Issue 1 (149). 2013 Volume 17 Issue 4 (148). 2013 Volume 17 Issue 4 (147). 2013 Volume 17 Issue 3 (146). 2013 Volume 17 Issue 3 (145). 2013 Volume 17 Issue 2 (144). 2013 Volume 17 Issue 2 (143).
Overview :: Pingtan Marine Enterprise, Ltd. (PME)
Go to Detailed Stock Info. View our latest Corporate Presentation. Aug 10, 2015 4:05 PM EDT. Pingtan Marine Enterprise Reports Financial Results For the Second Quarter and Six Months Ended June 30, 2015. Aug 4, 2015 8:30 AM EDT. Pingtan Marine Enterprise Schedules 2015 Second Quarter Financial Results And Conference Call. Jun 30, 2015 8:30 AM EDT. Pingtan Marine Enterprise Announces Purchase Of Six Internationally Licensed Fishing Vessels. Jun 4, 2015 8:30 AM EDT. May 11, 2015 4:05 PM EDT.
Imperium Rzymskie
Przybyłem, zobaczyłem, zwyciężyłem. Okazja dnia w RTV EURO AGD. Sprawdź! Witajcie bracia Rzymianie. Ogłaszam ukończenie prac nad tym miejscem dyskusji. Jeden z najwcześniejszych budynków wzniesionych na Forum Romanum, siedziba królów rzymskich. Rozporządzenie o armii i obronności. 2007-12-20 20:45:58 przez Hatton. Budynek na Forum Romanum przeznaczony na posiedzenia senatu. 2007-11-05 13:02:42 przez Merrox. Mównica wzniesiona na Forum Romanum. To z tego miejsca padają najważniejsza ogłoszenia. Wpisz swą ...
SOCIAL ENGAGEMENT